Available online 7 January 2022

Paediatric acute lymphoblastic leukaemia remains an active research area.

First line research: optimising multidrug chemotherapy and integrating new molecules.

Second- and third-line research: shift from intensification to precision medicine.

Academia is a pivotal stakeholder in childhood acute lymphoblastic leukaemia research.

The collaborative research model in acute lymphoblastic leukaemia should intensify.

New paediatric acute lymphoblastic leukaemia (ALL) treatments have been developed and innovative products are in the pipeline. However, despite many active clinical trials, bridging bench science to clinical development to authorised medicines remains challenging. Research in first-line treatment continues to focus on multidrug chemotherapy with the potential addition of new targeted molecules being studied. Research in second- and third-line treatment represents a shift from cytotoxic intensification to an area of precision medicine through emergent innovative and immuno-oncology products. The collaborative research model in ALL involving different stakeholders should intensify to facilitate bench-to-bedside clinical translation for the benefit of patients.

childhood acute lymphoblastic leukaemia

clinical drug development

clinical trials

research

oncology

EU regulation

© 2022 Elsevier Ltd. All rights reserved.